Company news

Inovio Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

October 12, 2022

INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

August 8, 2022

INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022

July 25, 2022

INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients

July 18, 2022

INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 30, 2022

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

June 26, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

May 26, 2022

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

May 9, 2022

INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

April 25, 2022

INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results

February 28, 2022

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

February 14, 2022

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

December 13, 2021

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

November 29, 2021

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

November 15, 2021

INOVIO Reports Third Quarter 2021 Financial Results

November 8, 2021

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

November 8, 2021

INOVIO Expands Executive Leadership to Prepare for Commercial Operations

November 4, 2021

INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

November 2, 2021

INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

October 26, 2021

INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

October 25, 2021

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

October 20, 2021

INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800

October 11, 2021

INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

October 10, 2021

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

September 21, 2021

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

August 25, 2021

INOVIO Reports Second Quarter 2021 Financial Results

August 8, 2021

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

August 8, 2021

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

August 3, 2021

INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

July 25, 2021

INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800

June 7, 2021

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

May 16, 2021

INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

May 11, 2021

INOVIO Reports First Quarter 2021 Financial Results

May 9, 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

May 9, 2021

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

April 26, 2021

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

April 22, 2021

INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

April 14, 2021

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

March 14, 2021

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

February 28, 2021

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

February 28, 2021

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

February 23, 2021

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

February 22, 2021

INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

February 15, 2021

INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

January 24, 2021

INOVIO Announces Proposed Public Offering of Common Stock

January 19, 2021

INOVIO Announces Pricing of Public Offering of Common Stock

January 19, 2021

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

January 5, 2021

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

January 3, 2021

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

December 23, 2020

INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China

December 9, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 26 decks. Every deck is listed under its year.